Everolimus

Abstract

Pneumonitis: 18 case reports In a retrospective study of 90 patients, 18 patients [ages and sexes not stated] were described, who developed pneumonitis with cryptogenic organising pneumonia pattern, non-specific interstitial pneumonia pattern or hypersensitivity pattern during treatment with everolimus for neuroendocrine neoplasm (NEN) [dosages, routes and durations of treatments to reactions onsets not stated]. The patients, who had NEN, started receiving everolimus. However, the patients developed grade 0–2 cough and grade 0–2 dyspnoea with a symptomatic score of 0–3. The CT scan showed cryptogenic organising pneumonia pattern (14 patients), nonspecific interstitial pneumonia pattern (3 patients) and hypersensitivity pattern (1 patient). The pneumonitis extent and interstitial lung disease score were found to be 1.67–42.5 and 105.83–250.83, respectively. Based on the clinical presentation and laboratory findings, CTCAE grade 1–2 everolimus-induced pneumonitis was considered. Out of these 18 patients, one patient was additionally found to have pulmonary effusion as secondary finding. Out of these 18 patients, the dose of everolimus was reduced in 16 patients. At last-follow-up, the pneumonitis improved in 4 patients and resolved in 14 patients.